LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

LLY

724.73

+1.52%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

Home・Aktien・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

7.62 -0.13

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.55

Max

7.62

Schlüsselkennzahlen
By Trading Economics
Einkommen	5.1M 5.1M
Verkäufe	18M 163M
Gewinnspanne	3.113
Angestellte	580
EBITDA	7.2M 28M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+129.36% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-172M 1.7B
Vorheriger Eröffnungskurs	7.75
Vorheriger Schlusskurs	7.62

Nachrichtenstimmung

By Acuity

50%

132 / 371 Ranking in Healthcare

BioCryst Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

26. Sept. 2025, 18:25 UTC

Wichtige Markttreiber

Mirion Technologies Stock Rises on Expanded Notes, Shares Offerings

27. Sept. 2025, 07:00 UTC

Ergebnisse

This Water Stock Is Dehydrated. What Could Bring It Back. -- Barrons.com

27. Sept. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. Sept. 2025, 21:56 UTC

Akquisitionen, Fusionen, Übernahmen

Staar Surgical, Insight Enterprises, and More Stocks See Action From Activist Investors -- Barrons.com

26. Sept. 2025, 20:54 UTC

Ergebnisse

U.S. TikTok for $14 Billion? Making Sense of the Bargain-Basement Price. -- Barrons.com

26. Sept. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. Sept. 2025, 20:27 UTC

Akquisitionen, Fusionen, Übernahmen

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. Sept. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

26. Sept. 2025, 19:54 UTC

Market Talk

Canada's Can't-Build Reputation Is Somewhat Earned -- Market Talk

26. Sept. 2025, 19:53 UTC

Akquisitionen, Fusionen, Übernahmen

Electronic Arts Stock Pops on Report Videogame Maker Is Close to Going Private -- Barrons.com

26. Sept. 2025, 19:40 UTC

Ergebnisse

The U.S. TikTok Is Apparently Fetching a Bargain-Basement Price. A Few Reasons Why. -- Barrons.com

26. Sept. 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Futures Mixed As October Expires -- Market Talk

26. Sept. 2025, 19:17 UTC

Market Talk

Oil Posts Weekly Gains on Russia-Ukraine Tensions -- Market Talk

26. Sept. 2025, 19:15 UTC

Market Talk

AI Deployment Beginning to Weigh on Job Creation, Former Central Banker Says -- Market Talk

26. Sept. 2025, 19:03 UTC

Market Talk

Global Equities Roundup: Market Talk

26. Sept. 2025, 19:03 UTC

Market Talk

Gold Fuels Stellar Performance in Toronto Stock Market -- Market Talk

26. Sept. 2025, 18:50 UTC

Market Talk

Ergebnisse

Costco's Executive Membership Gains Seen as Offsetting Slower Renewal Rates -- Market Talk

26. Sept. 2025, 18:36 UTC

Market Talk

Silver Closes Out Week With Strong Surge -- Market Talk

26. Sept. 2025, 18:02 UTC

Akquisitionen, Fusionen, Übernahmen

ING: Continue Working Towards Completing Transaction, Exit From Russian Market >ING

26. Sept. 2025, 18:02 UTC

Akquisitionen, Fusionen, Übernahmen

ING: Global Development Hasn't Received All Necessary Approvals >ING

26. Sept. 2025, 18:02 UTC

Akquisitionen, Fusionen, Übernahmen

ING: No Realistic Prospect of Completing Sale of ING Bank (Eurasia) to Global Development in 3Q

26. Sept. 2025, 17:54 UTC

Market Talk

U.S. Oil Rig Count Rises For Fifth Straight Week -- Market Talk

26. Sept. 2025, 16:56 UTC

Market Talk

Ergebnisse

Costco Increasingly Challenged to Meet Lofty Expectations -- Market Talk

26. Sept. 2025, 16:41 UTC

Market Talk

Ergebnisse

Costco's Valuation Seen as Too High Amid Slow Down -- Market Talk

26. Sept. 2025, 16:26 UTC

Ergebnisse

Correction to Sherwin-Williams Extends Losses. What's Ailing the Paint Maker. -- Barrons.com

26. Sept. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. Sept. 2025, 16:12 UTC

Market Talk

Nike Stock Seen With Limited Upside -- Market Talk

26. Sept. 2025, 15:59 UTC

Market Talk

Global Equities Roundup: Market Talk

26. Sept. 2025, 15:59 UTC

Market Talk

Nike Seen Showing Progress in Turnaround -- Market Talk

Peer-Vergleich

Kursveränderung

BioCryst Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

129.36% Vorteil

12-Monats-Prognose

Durchschnitt 17.5 USD 129.36%

Hoch 30 USD

Tief 12 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioCryst Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für BioCryst Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

132 / 371 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.